MLTX logo

MLTX
MoonLake Immunotherapeutics

5,890
Mkt Cap
$1.19B
Volume
133,130.00
52W High
$62.75
52W Low
$5.95
PE Ratio
-4.65
MLTX Fundamentals
Price
$16.72
Prev Close
$16.38
Open
$16.18
50D MA
$17.56
Beta
0.63
Avg. Volume
920,087.57
EPS (Annual)
-$3.53
P/B
3.84
Rev/Employee
$0.00
$531.37
Loading...
Loading...
News
all
press releases
The CEO of MoonLake Immunotherapeutics Dumped Shares Worth $2.8 Million. Should Investors Avoid the Stock?
Key PointsCEO Jorge Santos da Silva sold 150,000 shares for a transaction value of approximately ~$2.75 million, based on a weighted average sale price of $18.35 per share...
Nasdaq News: Markets·13d ago
News Placeholder
More News
News Placeholder
MoonLake Immunotherapeutics (NASDAQ:MLTX) CEO Sells $945,644.79 in Stock
MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) CEO Da Silva Jorge Santos sold 51,873 shares of the company's stock in a transaction dated Monday, April 13th. The shares were sold at an...
MarketBeat·16d ago
News Placeholder
MoonLake Immunotherapeutics (NASDAQ:MLTX) CEO Da Silva Jorge Santos Sells 98,127 Shares
MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) CEO Da Silva Jorge Santos sold 98,127 shares of the stock in a transaction on Friday, April 10th. The stock was sold at an average price of...
MarketBeat·17d ago
News Placeholder
MoonLake Immunotherapeutics (NASDAQ:MLTX) CEO Da Silva Jorge Santos Sells 51,873 Shares
MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) CEO Da Silva Jorge Santos sold 51,873 shares of MoonLake Immunotherapeutics stock in a transaction that occurred on Monday, April 13th. The...
MarketBeat·17d ago
News Placeholder
MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Down 6% - Here's Why
MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Down 6% - Time to Sell...
MarketBeat·21d ago
News Placeholder
JPMorgan Chase & Co. Buys 134,764 Shares of MoonLake Immunotherapeutics $MLTX
JPMorgan Chase & Co. increased its stake in MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 342.1% during the third quarter, according to the company in its most recent 13F filing with the...
MarketBeat·21d ago
News Placeholder
MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Average Recommendation of "Hold" from Analysts
MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) has received a consensus recommendation of "Hold" from the sixteen analysts that are currently covering the firm, Marketbeat Ratings...
MarketBeat·24d ago
News Placeholder
Insider Selling: MoonLake Immunotherapeutics (NASDAQ:MLTX) Director Sells 3,750,000 Shares of Stock
MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) Director Bvf Partners P/Il sold 3,750,000 shares of MoonLake Immunotherapeutics stock in a transaction dated Tuesday, March 31st. The shares were sold at an average price of $16.79, for a total transaction of $62,962,500.00. Following the...
MarketBeat·28d ago
News Placeholder
Bvf Partners P/Il Sells 3,750,000 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock
MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) Director Bvf Partners P/Il sold 3,750,000 shares of the stock in a transaction on Tuesday, March 31st. The stock was sold at an average...
MarketBeat·29d ago
News Placeholder
MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Down 12.8% - Here's Why
MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Down 12.8% - Here's What Happened...
MarketBeat·30d ago
<
1
2
...
>

Latest MLTX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.